Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826754 | 0.98 | SMO (0.48) | SMOFLT1PARP1HTTALDH1A1 | |
| SCHEMBL1830196 | 0.84 | FLT1 (0.43) | SMOFLT1PARP1HTTALDH1A1 | |
| SCHEMBL15038381 | 0.81 | SMO (0.47) | SMOFLT1PARP1HTTALDH1A1 | |
| SCHEMBL13491023 | 0.73 | SMO (0.62) | SMOPARP1HTTHTR2C | |
| SCHEMBL1828588 | 0.72 | SMO (0.46) | SMOFLT1HTTALDH1A1LMNA | |
| SCHEMBL7115917 | 0.71 | SMO (0.44) | SMOFLT1PARP1HTTLMNA | |
| SCHEMBL23886094 | 0.70 | NPC1 (0.39) | SMOPARP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL30020584 | 0.70 | NPC1 (0.39) | SMOPARP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL581560 | 0.69 | MAPK1 (0.32) | — | |
| SCHEMBL30375516 | 0.69 | MAPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2318389-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | SMO 1/4885FLT1 1714/4885PARP1 2643/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | SMO 1/4885FLT1 2671/4885PARP1 2966/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | SMO 1/4885FLT1 2671/4885PARP1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.